← Eichor
Study identifier: NCT04560322 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Condition: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma  ·  Sponsor: Massachusetts General Hospital

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalabrutinib

This description comes directly from the study's public registry record.

Talk to the study team

Jacob D Soumerai, MD  ·  617-724-4000  ·  jsoumerai@mgh.harvard.edu

Jacob D Soumerai, MD  ·  jsoumerai@mgh.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Massachusetts General Hospital Cancer CenterBoston, Massachusetts, United StatesRecruiting
Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesNot Yet Recruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04560322